All In Biotech

Drug Trial Radar · NCT06922305

Relative Bioavailability Study of HR19042 in Healthy Subjects

A Study on the Relative Bioavailability of HR19042 Capsules in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Dec 27, 2023

Primary completion

Jan 25, 2024

Study completion Jan 25, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, open-label, three-period, dual Latin square crossover study. Primary Objective: 1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release capsules (Tarpeyo®) and budesonide enteric-coated capsules (Budenofalk®). Secondary Objective 2. To assess safety following administration.

Conditions

  • Primary IgA Nephropathy; Autoimmune Hepatitis

Interventions

  • HR19042 Capsule, Tarpeyo®, Budenofalk®Drug

    In each period under fasting conditions, subjects received oral administration of either HR19042 Capsule 16 mg, Tarpeyo® 16 mg, or Budenofalk® 15 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax: Maximum plasma concentration. Blood samples will be collected.Time frame: From Day 1 up to Day 8
  2. AUC0-t: Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration. Blood samples will be collected.Time frame: From Day 1 up to Day 8
  3. AUC0-∞: Area under the plasma concentration-time curve from time 0 to infinity. Blood samples will be collected.Time frame: From Day 1 up to Day 8
  4. Tmax: Observed time to reach Cmax. Blood samples will be collected.Time frame: From Day 1 up to Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.